| Product Name | Human Ras-related protein Rap-1b (RAP1B) ELISA Kit |
|---|---|
| Description | The deduced 184-amino acid protein is 95% identical to RAP1A. RAP1B shares several properties with the RAS protein, suggesting that it may bind GTP/GDP and have a membrane location.RAP1B is mainly located at the membrane, but translocates to the cytosol upon activation. In activated platelets, RAP1B interacts with the reorganized actin-based cytoskeleton. RAP1B is activated by phosphorylation, increased intracellular Ca(2+), and by agonist-induced stimulation of Gi, which results in the rapid binding of GTP to RAP1B. RAP1B is posttranslationally modified by the geranylgeranylation of cys181. Further modifications cause proteolytic removal of the last 3 C-terminal amino acids, followed by partial methylation of the remaining terminal cysteinyl carboxyl group. This assay has high sensitivity and excellent specificity for detection of Human RAP1B. No significant cross-reactivity or interference between Human RAP1B and analogues was observed. |
| Synonyms | DKFZp586H0723, K-REV, RAL1B, RAS-related protein RAP1B|Ras family small GTP binding protein RAP1B|small GTP binding protein |
| Method | Sandwich ELISA |
| Detection Range | 23.44-1500 pg/mL |
| Sensitivity | 5.86 pg/mL |
| Reactivity | Human |
| Sample Types | Serum, Plasma, Other biological fluids. |
| Background | The deduced 184-amino acid protein is 95% identical to RAP1A. RAP1B shares several properties with the RAS protein, suggesting that it may bind GTP/GDP and have a membrane location.RAP1B is mainly located at the membrane, but translocates to the cytosol upon activation. In activated platelets, RAP1B interacts with the reorganized actin-based cytoskeleton. RAP1B is activated by phosphorylation, increased intracellular Ca(2+), and by agonist-induced stimulation of Gi, which results in the rapid binding of GTP to RAP1B. RAP1B is posttranslationally modified by the geranylgeranylation of cys181. Further modifications cause proteolytic removal of the last 3 C-terminal amino acids, followed by partial methylation of the remaining terminal cysteinyl carboxyl group. |
| Supplier | Abebio |
All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
